Trial Profile
A Non-Inferiority Study Evaluating Fibroblast Growth Factor-2 (KCB-1D) to Enamel Matrix Derivative (Emdogain(R)Gel) for Periodontal Tissue Regeneration.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Trafermin (Primary) ; Amelogenin
- Indications Periodontitis
- Focus Therapeutic Use
- Sponsors Kaken Pharmaceutical
- 22 Feb 2017 New trial record